HDAC6 inhibitors have demonstrated promising anti-MM activity by disrupting aggresome-mediated protein degradation and enhancing the cytotoxic effects of PIs, thereby offering a potential strategy to overcome drug resistance in MM [20,56], supporting the therapeutic relevance of HDAC6 targeting in this cancer. The gene discussed is HDAC6; the disease is Miyoshi myopathy.